10:10in productionCh. 1 · Basel, not Boston/ 10:10 · ceiling 15 min
Companies
Roche
1896
Roche isn’t a biotech pioneer — it’s a precision acquirer that turns diagnostics and drugs into a single revenue stream.
Roche is a Swiss multinational holding healthcare company founded in 1896, headquartered in Basel, operating through Pharmaceuticals and Diagnostics divisions. It is the fifth-largest pharmaceutical company by revenue and the global leader in cancer treatments. It owns Genentech, Chugai Pharmaceuticals, Ventana, and Foundation Medicine as subsidiaries. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. In 2023, it ranked 76th in the Forbes Global 2000.
Roche is a Swiss holding company headquartered in Basel — not a startup, not a foundation, but a century-old corporate structure built for scale.
2:26
Fifth by revenue, first in cancer
It ranks fifth by pharmaceutical revenue and leads globally in cancer treatments — but those are separate metrics, not proof of market control across oncology.
5:17
Owned, not partnered
Genentech and Chugai are wholly owned subsidiaries — meaning Roche absorbs their R&D costs and captures their profits, but also bears their regulatory and commercial risks.
6:30
Listed, ranked, consolidated
Its shares trade on the SIX Swiss Exchange, and its Forbes Global 2000 rank (76th in 2023) reflects consolidated financials — not standalone pharmaceutical or diagnostics performance.
Worth your time?
Yes. Study the whole thing.
4/ 5
What works
Dual-division structure aligning drug and diagnostic development.
Acquisition and integration of specialised biotech and diagnostics firms.
Global commercial infrastructure supporting high-cost targeted therapies.
What does not
Roche's leadership in cancer treatments extends to all oncology indications.
Roche controls pricing or reimbursement decisions in national health systems.
Strategy teams benchmarking acquisition-led growth in pharma.
Skip it if
Startups seeking validation of disruptive biotech models.
Policy makers looking for alternatives to patent-driven innovation.
The written brief1 min read
What the company or idea is
Roche is a Swiss multinational holding healthcare company founded in 1896, headquartered in Basel, with publicly listed shares on the SIX Swiss Exchange.
How it actually makes money
Roche makes money through two divisions: Pharmaceuticals and Diagnostics. Its revenue comes from selling cancer treatments, diagnostic instruments and tests, and related services globally.
What works
Its dual-division structure links drug development with diagnostic testing, enabling companion diagnostics that support regulatory approval and clinical adoption of targeted therapies.
What does not
Roche does not control pricing or reimbursement decisions in most national health systems. Its leadership in cancer treatments does not extend to all oncology indications or to early-stage prevention.
What to take from it
Roche shows how a century-old firm sustains dominance not through innovation alone, but by acquiring and integrating specialised biotech and diagnostics firms — Genentech, Chugai, Ventana, Foundation Medicine — into a coordinated commercial engine.
Is it worth your time
Yes — if you are assessing how scale, vertical integration, and acquisition strategy operate in regulated healthcare markets.
Rolex didn’t win the luxury watch race by selling dreams — it won by certifying time, replacing watches for POWs, and controlling every gear in between.